Postoperative Residual CurarisationNCT01362647
Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit
An observational study of Postoperative Residual Curarisation and Postoperative Hypoxemia, run by Onze Lieve Vrouw Hospital at 1 site in Belgium.
Trial summary
Several studies have documented that neuromuscular block often persists in the postanesthesia care unit (PACU). Residual paralysis is associated with postoperative complications such as hypoxia, weakness, and respiratory failure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Postoperative Residual Curarisation, Postoperative Hypoxemia, Postoperative Airway Obstruction
- What is being tested?
- neuromuscular transmission monitoring and Pulse oximetry measurement
- Type of treatment
- Surgery or procedure
- How many people
- 625 participants
- Where
- 1 siteBelgium
- Study dates
- May 2011to Oct 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will comprise about 600 surgical patients (the first 600 inpatients and outpatients scheduled for anesthesia during the study period who meet the study criteria).
Who may be able to join
- 18 years of age or older;
- Informed consent signed;
- Admission for elective surgery;
- Administration of non-depolarizing NMBDs during surgery;
- Tracheal intubation
Who cannot join
- Evidence of renal, hepatic, metabolic, and/or neuromuscular disorders
- Ejection fraction <20%
- Admission for emergency surgery; or cardiothoracic surgery
- Reoperation during the same hospital admission
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Non-interventional / Observational Study on Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit After Spontaneous Recovery or After Reversal of the Neuromuscular Block
Several studies have documented that neuromuscular block often persists in the postanesthesia care unit (PACU). Residual paralysis is associated with postoperative complications such as hypoxia, weakness, and respiratory failure. The data in the current literature on residual paralysis in the PACU were almost exclusively obtained with acetylcholinesterase inhibitors as they were the only reversal agents available prior to the introduction in clinical practice of sugammadex (Bridion®) in the European Union and in some other countries, except for the USA. Reassessment of practice in this regard is relevant, now that sugammadex (Bridion®) has become available in our country since 2009.
This study is an observational/non-interventional, non-randomized study involving adult patients undergoing different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking drugs (NMBDs). Administration of NMBDs and reversal agents (as well as all drugs which will be used during anesthesia) will be performed in accordance with routine anesthetic practice.
Read more
The study population will comprise about 600 surgical patients. Immediately after the patients' arrival in the PACU, a study nurse will record the acceleromyographic responses of their adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve. A TOF of 90% will be used as cut-off value to exclude residual paralysis. Pulse oximetry (SpO2) will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min. PACU nurses caring for the patient will document the occurrence of any of the following events during the first 30 min of PACU admission: the number of episodes of hypoxemia (SpO2<90%), the lowest SpO2 observed by nursing staff, the requirement for either tactile or verbal stimulation to maintain SpO2 greater than 90%, and any clinical evidence of airway obstruction.
The primary objective is to evaluate the incidence of postoperative residual curarisation at PACU arrival in patients reversed with sugammadex (Bridion®), neostigmine and in case of spontaneous recovery.
The secondary objectives are to evaluate:
- Oxygen saturation (SpO2) at PACU arrival
- Possible episodes of SpO2 <90% in the PACU
- Airway maneuvers and/or stimulation required to maintain SpO2 >90% in the PACU
- Need for re-intubation.
Read the detailed description
- Background \& Rationale: Several studies have documented that neuromuscular block often persists in the PACU, even with the administration of acetylcholinesterase inhibitors. Postoperative residual curarisation ranges between 4 and 50% depending on the diagnostic criteria, the type of non-depolarizing neuromuscular blocking drug (NMBD), the administration of a reversal agent, and the use of neuromuscular monitoring. Residual paralysis is associated with postoperative complications such as hypoxia, weakness, and respiratory failure. However, these complications may have many other causes so that the role of neuromuscular block is often unrecognized. Thus, it is important to manage neuromuscular block and have a strategy to prevent, diagnose, and treat residual paralysis, with neuromuscular monitoring and reversal of neuromuscular block in routine anesthetic practice. The data in the current literature on residual paralysis in the PACU were almost exclusively obtained with acetylcholinesterase inhibitors as they were the only reversal agents available prior to the introduction in clinical practice of sugammadex (Bridion®) in the European Union and in some other countries, except for the USA. Reassessment of practice in this regard is relevant, now that sugammadex (Bridion®) has become available in our country since 2009.
Five years ago a similar exploratory, non-interventional, non-randomized study took place in Belgium. This previous study will help to assess the two different periods (2005-2011) in terms of management of neuromuscular block in the operating room of a large regional community hospital.
- Study Design: This is an observational/non-interventional, non-randomized study involving adult patients undergoing different types of elective surgical procedures requiring general anesthesia with NMBDs. This study will reflect real life clinical practice. The anesthetic technique in terms of drugs and type of monitoring used will be the entire responsibility of the anesthesiologist.
All study activities will be consistent with EU directive 2001/20/EC for non-interventional studies (also known as observational/non-interventional studies).
Administration of NMBDs and reversal agents (as well as all drugs which will be used during anesthesia) will be performed in accordance with routine anesthetic practice; will follow good clinical practice and labeling of drugs. No other interventional means, methods or procedures are scheduled than those for routine care of the patient. Furthermore, there will be no additional visits to the hospital or a mandatory visit schedule, deviating from normal clinical practice.
- Study Flowchart: On arrival to the PACU, 3 l/min oxygen will be applied to all subjects by a nasal cannula. Baseline oxygen saturation values are recorded 1 min after application of the oxygen. Immediately after the patients' arrival in the PACU, a study nurse will record their tympanic temperatures and the acceleromyographic responses of their adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve (TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland). The stimulus current will be set in the range 25-35 mA for tolerance purpose without compromising the results. Two consecutive TOF measurements (separated by 15 s) will be obtained, and the average of the 2 values will be recorded. If measurements differ by >10%, additional TOF measurements will be obtained (up to 4 TOF values), and the closest 2 ratios averaged. A TOF of 90% will be used as cut-off value to exclude residual paralysis. Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min. PACU nurses caring for the patient will document the occurrence of any of the following events during the first 30 min of PACU admission: the number of episodes of hypoxemia (SpO2<90%), the lowest SpO2 observed by nursing staff, the requirement for either tactile or verbal stimulation to maintain SpO2 greater than 90%, and any clinical evidence of airway obstruction. Patient demographic data, type of surgical procedure, duration of anesthesia, as well as data collected relating to neuromuscular management, will be recorded and stored on a PC.
- Conditions
- Postoperative Residual Curarisation, Postoperative Hypoxemia, Postoperative Airway Obstruction
- Being tested
- neuromuscular transmission monitoring, Pulse oximetry measurement
- Keywords
- Muscle Relaxation
- Medical subject headings
- Delayed Emergence from Anesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
neuromuscular transmission monitoringProcedure or surgery
The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
Pulse oximetry measurementProcedure or surgery
Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of postoperative residual curarisation
incidence of postoperative residual curarisation (PORC) defined by a train-of-four (TOF) ratio < 0,9 at post-anesthesia care unit (PACU) arrival
Measured: Immediately after the patients' arrival in the post-anesthesia care unit (<5 min after arrival), two consecutive neuromuscular transmission measurements (separated by 15 s) will be obtained, and the average of the 2 values will be recorded.
Secondary outcomes (3)
Possible episodes of SpO2 <90% in the PACU
Measured: During the first 30 min of PACU admission
Airway maneuvers and/or stimulation required to maintain SpO2 >90% in the PACU
the requirement for either tactile or verbal stimulation to maintain SpO2 greater than 90%, and any clinical evidence of airway obstruction
Measured: During the first 30 min of PACU admission
Need for re-intubation
Measured: During the first 30 min of PACU admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2011 (estimated)
- Study startMay 2011
- Primary completionOct 2011
- Study completionOct 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Postoperative Residual CurarisationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 625 participants (actual)
Sponsor and investigators
- Lead sponsor
- Onze Lieve Vrouw Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- Investigators
- Guy Cammu, MD, PhD, Principal investigator, OLV Hospital, Aalst, Belgium
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01362647
- Sponsor's protocol ID
- B126201110617
- Other IDs
- IISP ID 39443
- Status last verified
- Oct 2011
- First submitted
- 25 May 2011
- Last updated
- 5 Oct 2011
- Results posted
- No
- Data monitoring committee
- No
Publications
Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L, Vandenbroucke G, Deloof T. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006 Feb;102(2):426-9. doi: 10.1213/01.ane.0000195543.61123.1f.
PubMed 16428537
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Non-interventional / Observational Study on Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit After Spontaneous Recovery or After Reversal of the Neuromuscular Block
- ClinicalTrials.gov ID
- NCT01362647
- Acronym / sponsor ID
- B126201110617
- Conditions
- Postoperative Residual Curarisation, Postoperative Hypoxemia, Postoperative Airway Obstruction
- Keywords
- Muscle Relaxation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 625 participants (actual)
- Lead sponsor
- Onze Lieve Vrouw HospitalUniversity, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- Study start
- May 2011
- Primary completion
- Oct 2011 (actual)
- Study completion
- Oct 2011 (actual)
- First posted
- 30 May 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Several studies have documented that neuromuscular block often persists in the postanesthesia care unit (PACU). Residual paralysis is associated with postoperative complications such as hypoxia, weakness, and respiratory failure. The data in the current literature on residual paralysis in the PACU were almost exclusively obtained with acetylcholinesterase inhibitors as they were the only reversal agents available prior to the introduction in clinical practice of sugammadex (Bridion®) in the European Union and in some other countries, except for the USA. Reassessment of practice in this regard is relevant, now that sugammadex (Bridion®) has become available in our country since 2009.
This study is an observational/non-interventional, non-randomized study involving adult patients undergoing different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking drugs (NMBDs). Administration of NMBDs and reversal agents (as well as all drugs which will be used during anesthesia) will be performed in accordance with routine anesthetic practice.
The study population will comprise about 600 surgical patients. Immediately after the patients' arrival in the PACU, a study nurse will record the acceleromyographic responses of their adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve. A TOF of 90% will be used as cut-off value to exclude residual paralysis. Pulse oximetry (SpO2) will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min. PACU nurses caring for the patient will document the occurrence of any of the following events during the first 30 min of PACU admission: the number of episodes of hypoxemia (SpO2<90%), the lowest SpO2 observed by nursing staff, the requirement for either tactile or verbal stimulation to maintain SpO2 greater than 90%, and any clinical evidence of airway obstruction.
The primary objective is to evaluate the incidence of postoperative residual curarisation at PACU arrival in patients reversed with sugammadex (Bridion®), neostigmine and in case of spontaneous recovery.
The secondary objectives are to evaluate:
- Oxygen saturation (SpO2) at PACU arrival
- Possible episodes of SpO2 <90% in the PACU
- Airway maneuvers and/or stimulation required to maintain SpO2 >90% in the PACU
- Need for re-intubation.
Detailed description
- Background \& Rationale: Several studies have documented that neuromuscular block often persists in the PACU, even with the administration of acetylcholinesterase inhibitors. Postoperative residual curarisation ranges between 4 and 50% depending on the diagnostic criteria, the type of non-depolarizing neuromuscular blocking drug (NMBD), the administration of a reversal agent, and the use of neuromuscular monitoring. Residual paralysis is associated with postoperative complications such as hypoxia, weakness, and respiratory failure. However, these complications may have many other causes so that the role of neuromuscular block is often unrecognized. Thus, it is important to manage neuromuscular block and have a strategy to prevent, diagnose, and treat residual paralysis, with neuromuscular monitoring and reversal of neuromuscular block in routine anesthetic practice. The data in the current literature on residual paralysis in the PACU were almost exclusively obtained with acetylcholinesterase inhibitors as they were the only reversal agents available prior to the introduction in clinical practice of sugammadex (Bridion®) in the European Union and in some other countries, except for the USA. Reassessment of practice in this regard is relevant, now that sugammadex (Bridion®) has become available in our country since 2009.
Five years ago a similar exploratory, non-interventional, non-randomized study took place in Belgium. This previous study will help to assess the two different periods (2005-2011) in terms of management of neuromuscular block in the operating room of a large regional community hospital.
- Study Design: This is an observational/non-interventional, non-randomized study involving adult patients undergoing different types of elective surgical procedures requiring general anesthesia with NMBDs. This study will reflect real life clinical practice. The anesthetic technique in terms of drugs and type of monitoring used will be the entire responsibility of the anesthesiologist.
All study activities will be consistent with EU directive 2001/20/EC for non-interventional studies (also known as observational/non-interventional studies).
Administration of NMBDs and reversal agents (as well as all drugs which will be used during anesthesia) will be performed in accordance with routine anesthetic practice; will follow good clinical practice and labeling of drugs. No other interventional means, methods or procedures are scheduled than those for routine care of the patient. Furthermore, there will be no additional visits to the hospital or a mandatory visit schedule, deviating from normal clinical practice.
- Study Flowchart: On arrival to the PACU, 3 l/min oxygen will be applied to all subjects by a nasal cannula. Baseline oxygen saturation values are recorded 1 min after application of the oxygen. Immediately after the patients' arrival in the PACU, a study nurse will record their tympanic temperatures and the acceleromyographic responses of their adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve (TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland). The stimulus current will be set in the range 25-35 mA for tolerance purpose without compromising the results. Two consecutive TOF measurements (separated by 15 s) will be obtained, and the average of the 2 values will be recorded. If measurements differ by >10%, additional TOF measurements will be obtained (up to 4 TOF values), and the closest 2 ratios averaged. A TOF of 90% will be used as cut-off value to exclude residual paralysis. Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min. PACU nurses caring for the patient will document the occurrence of any of the following events during the first 30 min of PACU admission: the number of episodes of hypoxemia (SpO2<90%), the lowest SpO2 observed by nursing staff, the requirement for either tactile or verbal stimulation to maintain SpO2 greater than 90%, and any clinical evidence of airway obstruction. Patient demographic data, type of surgical procedure, duration of anesthesia, as well as data collected relating to neuromuscular management, will be recorded and stored on a PC.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will comprise about 600 surgical patients (the first 600 inpatients and outpatients scheduled for anesthesia during the study period who meet the study criteria).
Key inclusion criteria (5 listed)
- 18 years of age or older;
- Informed consent signed;
- Admission for elective surgery;
- Administration of non-depolarizing NMBDs during surgery;
- Tracheal intubation
Key exclusion criteria (4 listed)
- Evidence of renal, hepatic, metabolic, and/or neuromuscular disorders
- Ejection fraction <20%
- Admission for emergency surgery; or cardiothoracic surgery
- Reoperation during the same hospital admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| neuromuscular transmission monitoringThe acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland. | Procedure or surgery | – |
| Pulse oximetry measurementPulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min. | Procedure or surgery | – |
Primary outcome
incidence of postoperative residual curarisation
Time frame: Immediately after the patients' arrival in the post-anesthesia care unit (<5 min after arrival), two consecutive neuromuscular transmission measurements (separated by 15 s) will be obtained, and the average of the 2 values will be recorded.
incidence of postoperative residual curarisation (PORC) defined by a train-of-four (TOF) ratio < 0,9 at post-anesthesia care unit (PACU) arrival
3 secondary outcomes
Possible episodes of SpO2 <90% in the PACU
Time frame: During the first 30 min of PACU admission
Airway maneuvers and/or stimulation required to maintain SpO2 >90% in the PACU
Time frame: During the first 30 min of PACU admission
Need for re-intubation
Time frame: During the first 30 min of PACU admission
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2011.
- Background: PubMed 16428537Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L, Vandenbroucke G, Deloof T. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006 Feb;102(2):426-9. doi: 10.1213/01.ane.0000195543.61123.1f.
Related trials for Postoperative Residual Curarisation
Not yet recruitingObservational study
Diaphragm Ultrasound and Neuromuscular Monitoring for Predicting Early Respiratory Events After Extubation
Residual Neuromuscular Blockade, Diaphragm Dysfunction
RecruitingObservational study
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
Muscle Relaxants
Not yet recruitingObservational study
Postoperative Residual Neuromuscular Block and Passive Smoke Exposure in Pediatric Dental Patients
Postoperative Residual Curarization, Neuromuscular Block Prolonged
Not yet recruitingObservational study
Acceleromyography Versus Electromyography for Neuromuscular Recovery Assessment at the End of Surgery
Neuromuscular Blockade, Cholecystectomy
Recruiting
Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function
Residual Neuromuscular Block
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Guy Cammu, MD, PhD principal investigator
OLV Hospital, Aalst, Belgium
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Postoperative Residual Curarisation and Postoperative Hypoxemia, run by Onze Lieve Vrouw Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of postoperative residual curarisation (time frame: Immediately after the patients' arrival in the post-anesthesia care unit (<5 min after arrival), two consecutive neuromuscular transmission measurements (separated by 15 s) will be obtained, and the average of the 2 values will be recorded.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01362647, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2011.